| pubmed-article:3816879 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3816879 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:3816879 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:3816879 | lifeskim:mentions | umls-concept:C0001563 | lld:lifeskim |
| pubmed-article:3816879 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:3816879 | lifeskim:mentions | umls-concept:C0063103 | lld:lifeskim |
| pubmed-article:3816879 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3816879 | pubmed:dateCreated | 1987-4-1 | lld:pubmed |
| pubmed-article:3816879 | pubmed:abstractText | The pharmacokinetics of hydroxy-3(S)-dihydroquinidine (HDHQ) were studied in 6 healthy volunteers following a 15 min intravenous infusion of a 300 or 400 mg dose, a 300 mg oral dose in solution and a 300 mg tablet administration on three separate occasions (random order) with at least one week intervals. Using a specific HPLC assay for HDHQ, the post-infusion and post-absorption plasma HDHQ concentrations declined bi-exponentially. Both oral forms of HDHQ were absorbed rapidly (tmax 1 h-1.2 h) with an absolute bioavailability of the oral solution (F = 0.54 to 0.93) which was not significantly different from that of the tablet (F = 0.66 to 0.90). HDHQ was rapidly and extensively distributed to the tissues with a high steady-state volume of distribution (6.82 +/- 1.85 l X kg-1). Mean elimination half-life was 6.7 +/- 1.4 h after IV infusion, 8.4 +/- 1.7 h after the oral solution and 11.3 +/- 4.4 h after the tablet administration. HDHQ was partially eliminated from the body in the unchanged non-conjugated form by the urine and renal clearance represented approximately 50% of the total body clearance. These results show that HDHQ is rapidly and almost completely absorbed and has potential for a twice daily administration regimen for the treatment of cardiac arrhythmias. | lld:pubmed |
| pubmed-article:3816879 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3816879 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3816879 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3816879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3816879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3816879 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3816879 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3816879 | pubmed:issn | 0378-7966 | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:CheymolGG | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:PaysMM | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:JaillonPP | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:PoirierJ MJM | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:RichardM OMO | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:JarreauCC | lld:pubmed |
| pubmed-article:3816879 | pubmed:author | pubmed-author:LecocqBB | lld:pubmed |
| pubmed-article:3816879 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3816879 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:3816879 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3816879 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3816879 | pubmed:pagination | 233-8 | lld:pubmed |
| pubmed-article:3816879 | pubmed:dateRevised | 2011-2-2 | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:meshHeading | pubmed-meshheading:3816879-... | lld:pubmed |
| pubmed-article:3816879 | pubmed:articleTitle | Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration. | lld:pubmed |
| pubmed-article:3816879 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3816879 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3816879 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
